No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Morgan Stanley Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $70
Cautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant Milestones
Express News | Cytokinetics Inc - Pdufa Target Action Date for Aficamten Set for September 26, 2025
Express News | Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
Cytokinetics Analyst Ratings
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference